Are Broad-spectrum Fluoroquinolones More Likely to Cause Clostridium Difficile-associated Disease?

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2006 Aug 31

PMID 16940135

Citations 12

Authors

Irfan A Dhalla

Muhammad M Mamdani

Andrew E Simor

Alex Kopp

Paula A Rochon

David N Juurlink

Affiliations

Soon will be listed here.

Abstract

Limited evidence suggests that broad-spectrum fluoroquinolones such as gatifloxacin and moxifloxacin are more likely to cause Clostridium difficile-associated disease than levofloxacin. In a population-based case-control study of outpatients prescribed fluoroquinolones, we found no increased risk of C. difficile-associated disease requiring hospitalization among patients prescribed gatifloxacin or moxifloxacin compared to levofloxacin.

Citing Articles

Safety of fluoroquinolones.

Barberan J, de la Cuerda A, Tejeda Gonzalez M, Lopez Aparicio A, Monfort Vinuesa C, Ramos Sanchez A Rev Esp Quimioter. 2023; 37(2):127-133.

PMID: 38140798 PMC: 10945095. DOI: 10.37201/req/143.2023.

Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?.

Rusu A, Munteanu A, Arbanasi E, Uivarosi V Pharmaceutics. 2023; 15(3).

PMID: 36986665 PMC: 10056716. DOI: 10.3390/pharmaceutics15030804.

Antibiotic-Specific Risk for Community-Acquired Infection in the United States from 2008 to 2020.

Zhang J, Chen L, Gomez-Simmonds A, Yin M, Freedberg D Antimicrob Agents Chemother. 2022; 66(12):e0112922.

PMID: 36377887 PMC: 9764966. DOI: 10.1128/aac.01129-22.

Corticosteroids Do Not Increase the Likelihood of Primary Infection in the Setting of Broad-Spectrum Antibiotic Use.

Carlson T, Gonzales-Luna A, Wilcox M, Theriault S, Alnezary F, Patel P Open Forum Infect Dis. 2021; 8(10):ofab419.

PMID: 34646906 PMC: 8501294. DOI: 10.1093/ofid/ofab419.

Antibiotic Prescribing Choices and Their Comparative C. Difficile Infection Risks: A Longitudinal Case-Cohort Study.

Brown K, Langford B, Schwartz K, Diong C, Garber G, Daneman N Clin Infect Dis. 2020; 72(5):836-844.

PMID: 32069358 PMC: 7935390. DOI: 10.1093/cid/ciaa124.

References

Biller P, Shank B, Lind L, Brennan M, Tkatch L, Killgore G . Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol. 2007; 28(2):198-201. DOI: 10.1086/511789. View

Levy A, OBrien B, Sellors C, Grootendorst P, Willison D . Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003; 10(2):67-71. View

Schneeweiss S, Seeger J, Maclure M, Wang P, Avorn J, Glynn R . Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001; 154(9):854-64. DOI: 10.1093/aje/154.9.854. View

Bignardi G . Risk factors for Clostridium difficile infection. J Hosp Infect. 1998; 40(1):1-15. DOI: 10.1016/s0195-6701(98)90019-6. View

Loo V, Poirier L, Miller M, Oughton M, Libman M, Michaud S . A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005; 353(23):2442-9. DOI: 10.1056/NEJMoa051639. View

Dial S, Delaney J, Barkun A, Suissa S . Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2006; 294(23):2989-95. DOI: 10.1001/jama.294.23.2989. View

Poutanen S, Simor A . Clostridium difficile-associated diarrhea in adults. CMAJ. 2004; 171(1):51-8. PMC: 437686. DOI: 10.1503/cmaj.1031189. View

Appelbaum P . Quinolone activity against anaerobes. Drugs. 1999; 58 Suppl 2:60-4. DOI: 10.2165/00003495-199958002-00012. View

Alter D, Naylor C, Austin P, Tu J . Long-term MI outcomes at hospitals with or without on-site revascularization. JAMA. 2001; 285(16):2101-8. DOI: 10.1001/jama.285.16.2101. View

10.

Linder J, Huang E, Steinman M, Gonzales R, Stafford R . Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med. 2005; 118(3):259-68. DOI: 10.1016/j.amjmed.2004.09.015. View

11.

Dallal R, Harbrecht B, Boujoukas A, Sirio C, Farkas L, Lee K . Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002; 235(3):363-72. PMC: 1422442. DOI: 10.1097/00000658-200203000-00008. View

12.

Gaynes R, Rimland D, Killum E, Lowery H, Johnson 2nd T, Killgore G . Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis. 2004; 38(5):640-5. DOI: 10.1086/381551. View

13.

Martinez F, Anzueto A . Appropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Am J Med. 2005; 118 Suppl 7A:39S-44S. DOI: 10.1016/j.amjmed.2005.05.012. View

14.

McDonald L, Killgore G, Thompson A, Owens Jr R, Kazakova S, Sambol S . An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005; 353(23):2433-41. DOI: 10.1056/NEJMoa051590. View

15.

McEllistrem M, Carman R, Gerding D, Genheimer C, Zheng L . A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis. 2005; 40(2):265-72. DOI: 10.1086/427113. View

16.

Zhanel G, Ennis K, Vercaigne L, Walkty A, Gin A, Embil J . A critical review of the fluoroquinolones: focus on respiratory infections. Drugs. 2002; 62(1):13-59. DOI: 10.2165/00003495-200262010-00002. View

17.

Ferrara A . New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance. Infection. 2005; 33(3):106-14. DOI: 10.1007/s15010-005-4102-8. View

18.

McCusker M, Harris A, Perencevich E, Roghmann M . Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis. 2003; 9(6):730-3. PMC: 3000134. DOI: 10.3201/eid0906.020385. View

19.

Stein G, Schooley S, Tyrrell K, Citron D, Goldstein E . Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum. Antimicrob Agents Chemother. 2003; 47(4):1308-12. PMC: 152495. DOI: 10.1128/AAC.47.4.1308-1312.2003. View

20.

Ko D, Mamdani M, Alter D . Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA. 2004; 291(15):1864-70. DOI: 10.1001/jama.291.15.1864. View